Skip to main content Skip to search Skip to main navigation

PMDA: Information on the procedure for remote inspections

In January 2021, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) published the English translation of the document on remote inspections, Procedure for Remote Inspection as a Part of Compliance Inspection on Drugs and Regenerative Medical Products.

The document describes the specific procedure for a remote inspection in five points.  A further four points clarify how to proceed with the necessary documents. Three points deal with the video conferencing system in more detail.

The procedure is usually as follows:

  1. The PMDA announces the inspection to the applicant as a remote inspection; if necessary, there is a pre-inspection meeting.
  2. The PMDA confirms the schedule of the pre-inspection and the method of presenting documentation approximately one to two months prior to the main inspection.
  3. The applicant grants the inspector access to the cloud system or sends the documentation on CD or DVD to PMDA.
  4. Information on sampling condition/scope of documentation will be provided to the applicant 13 business days prior to the main inspection.
  5. Within 10 business days prior to the main inspection, the applicant shares the documentation with the inspector(s).
  6. A pre-inspection, during which the documents are checked, takes place within 10 business days; if there are any concerns to be examined, the applicant is informed.
  7. During the main inspection using a video conferencing system, documents that could not be reviewed during the pre-inspection will be reviewed and the applicant will be interviewed about the concerns identified during the pre-inspection.
  8. After the inspection, the applicant should take action on the unresolved concerns as soon as possible.

PMDA: Procedure for Remote Inspection as a part of compliance inspection on drugs and regenerative medical product 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

What Types of Impurities may be Present in Active Substances?

What Types of Impurities may be Present in Active Substances?


Read more
There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

There’s Something in the Air – Cleanroom Technology in the Pharmaceutical Industry

In pharmaceutical manufacturing, clean air is not a subjective perception but a precisely controlled technical condition that is essential for product safety. Heating, ventilation and air-conditioning (HVAC) systems ensure, through airflow management, air filtration and pressure control, that particles and microorganisms are kept away from critical areas. This is based on clearly defined requirements for air changes, cleanliness classes, airflow patterns and pressure concepts, all of which are designed according to the manufacturing process and contamination risk involved.
Read more
EU: Analysis Supporting the Proposed Biotech Act

EU: Analysis Supporting the Proposed Biotech Act

The European Commission has published the analysis underpinning the proposed Biotech Act. The initiative aims to strengthen Europe’s biotechnology and biomanufacturing sectors and to accelerate the development, production and market uptake of biotechnology-based innovations.
Read more
EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

EFPIA: Results of the Member Survey 2025 on GMP and GDP Inspections

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published the results of its “Annual Regulatory GMP/GDP Inspection Survey 2025”. The data suggest that international GMP inspections are increasingly being replaced by reliance and work-sharing approaches between inspectorates.
Read more
What are the Core Tasks of Human Resource Management?

What are the Core Tasks of Human Resource Management?

Here's the answer:
Read more
European GMP Regulations: Ongoing Changes and What Lies Ahead

European GMP Regulations: Ongoing Changes and What Lies Ahead

At the 2026 ISPE European Annual Conference in Copenhagen, Brendan Cuddy (EMA) provided a concise update on current European GMP regulatory developments and the work of the GMP/GDP Inspectors Working Group (GMDP IWG).
Read more
Previous
Next